Markets/ForexArticle

Novartis Phase III trial results for del-desiran from the Avidity acquisition miss primary endpoints in treating myotonic dystrophy type 1

Finance Review Daily is tracking this developing story; additional confirmed specifics had not been verified at the time of publication.

SL

Sophie Laurent · FX & Rates Desk · 14 Sept 2026 · 15:57 · 1 min read

Share

Novartis Phase III trial results for del-desiran from the Avidity acquisition miss primary endpoints in treating myotonic dystrophy type 1.

Euro / US Dollar

EURUSD

Full profile →

1.1541▼ 0.50%

As of 13/09/2026, 21:00:00

Finance Review Daily is tracking this development following a report from the original source. Additional confirmed specifics had not been verified at the time of publication.

This article was produced with AI assistance and edited by a Finance Review Daily journalist.

Share this story

SL

Written by

Sophie Laurent

FX & Rates Desk

Sophie covers currency markets and central bank policy across Europe, with a focus on how rate decisions ripple through FX pairs. She has been tracking the ECB's policy path since the start of the current easing cycle.

Market Snapshot

Delayed

EUR/USD1.1541▼ 0.50%GBP/USD1.3482▼ 0.33%USD/CHF0.8186▲ 0.26%BTC/USD78,185.64▲ 1.75%ETH/USD2,518.57▲ 1.67%XAU/USD4,287.04▼ 1.41%

Novartis Phase III trial results for del-desiran from the Avidity acquisition miss primary endpoints in treating myotonic dystrophy type 1

Euro / US Dollar

Market Snapshot

Related Reading

iBio’s obesity pipeline advances with long-acting antibody IBIO-610, Q3 2027 trial targets

Yen strengthens as BOJ hawkish signals lift government bond yields

InnovAge Posts Record Fiscal 2026 Profit, Shares Surge After Market Close

Rivian Says R2 Pre-orders Exceed Supply Plans, Targets Profitability by Late 2026

Nutanix Says Cloud Push Is Gaining Pace as Margin Target Rises